STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 28, 2001. STAAR Surgical Company develops, manufactures, and distributes medical devices for minimally invasive ophthalmic surgery, including intraocular lenses (IOLs) and phacoemulsification systems. The company operates manufacturing sites in the United States and Switzerland and markets products in over 40 countries.
Key Financial Metrics
| Metric | Three Months Ended Sep 28, 2001 | Nine Months Ended Sep 28, 2001 | Nine Months Ended Sep 29, 2000 |
|---|---|---|---|
| Total Revenues | $12.2 million | $38.0 million | $40.7 million |
| Gross Profit | $6.7 million (55.0% margin) | $16.4 million (43.0% margin) | $19.7 million (48.4% margin) |
| Operating Loss | $(2.9) million | $(10.2) million | $(19.4) million |
| Net Loss | $(2.0) million | $(6.4) million | $(17.7) million |
| Cash and Equivalents | $2.4 million | $2.4 million (End of Period) | $21.8 million (End of Period) |
| Notes Payable | $8.2 million | $8.2 million | $7.9 million (Dec 29, 2000) |
| Working Capital | $16.6 million | $16.6 million | $24.3 million (Dec 29, 2000) |
Material Changes vs. Prior Period
- Revenue Decline: Nine-month revenues decreased 6.4% year-over-year, driven by discontinued operations in 2000 and a product recall affecting Elastic and Elastimide silicone IOLs in Q2 2001.
- Margin Compression: Gross margin for the nine months dropped to 43.0% from 48.4% in the prior year. This was significantly impacted by $5.6 million in charges to cost of sales, including $3.6 million for product recalls and $2.0 million for excess/obsolete inventory.
- Non-Recurring Charges: The company recorded a $2.1 million reserve against notes receivable from directors in Q3 2001. Restructuring charges for the nine months were $2.1 million, a significant decrease from $13.8 million in the prior year.
- Cash Position: Cash and cash equivalents decreased by approximately $3.7 million from the beginning of the year to fund operations and pay down debt.
Outlook, Risks, and Management Commentary
- Covenant Waiver: The company is not in compliance with the net income covenant of its $7.0 million line of credit. A waiver was obtained from the lender, and the note maturity was extended to January 4, 2002. Management is seeking alternative financing to pay down or refinance this debt.
- Strategic Restructuring: A new business strategy involves consolidating manufacturing to Switzerland and reducing capacity in California. This may result in approximately $5.3 million in fixed asset write-offs and other charges in Q4 2001.
- Legal Resolution: Disputes with Canon Inc. regarding their Japanese joint venture were resolved, reaffirming the partnership and eliminating previous write-offs associated with the venture.
- Future Profitability: Management expects to return to profitability through new product introductions (Toric, Collamer IOLs, Aquaflow device) and cost savings measures, though near-term unit costs for IOLs are expected to rise due to lower production volumes.
Investor Verification Checklist
- Debt Refinancing: Verify the status of the company's efforts to secure alternative financing to replace the current credit facility before the January 2002 maturity.
- Q4 Charges: Monitor the fourth quarter for the anticipated $5.3 million in charges related to manufacturing consolidation and subsidiary closures.
- Inventory Levels: Assess the impact of the $5.6 million inventory write-downs on future cost of sales and gross margins as production levels stabilize.
- Product Recall Impact: Evaluate the long-term effect of the silicone IOL recall on market share and sales of the Elastic and Elastimide product lines.
- Legal Contingencies: Review the status of the ongoing litigation with former CEO John R. Wolf regarding wrongful termination and stock options.